No Data
No Data
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), a late clinical-stage biopharmaceutical company focused on developing the first aceclid
Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400
Sarepta Therapeutics (SRPT) is set to replace Shockwave Medical (SWAV) in the S&P MidCap 400 effective June 3, according to a late Wednesday statement from S&P Dow Jones Indices. Johnson & Johnson (JN
Cutia Therapeutics' Atopic Dermatitis Drug Advances
United States Sex Reassignment Hormone Therapy Research Report 2024 Featuring Viatris, AbbVie, ASCEND Therapeutics, Pfizer, Eli Lilly and Co, Novartis, Endo International
Enlivex Therapeutics Announces New Securities Deal
No Data